Target intelligence / Profile preview

Basic helix-loop-helix ARNT-like protein 1 (BMAL1)

Target
BMAL1
Molecular classification
Transcription factor, Basic helix-loop-helix (bHLH) protein, PAS domain protein (Per-Arnt-Sim domain protein)
01

Overview

Basic helix-loop-helix ARNT-like protein 1 (BMAL1) is a core circadian transcription factor, encoded by the ARNTL gene in humans, and is essential for generating and maintaining circadian rhythmicity in both behavior and physiology. BMAL1 forms heterodimers with CLOCK, another bHLH-PAS transcription factor; this complex binds E-box motifs in DNA to drive rhythmic expression of a broad set of clock-controlled genes, including other clock regulators such as PER and CRY family members. BMAL1 influences numerous biological processes, including metabolism, immune cell function (such as pro-inflammatory cytokine production in macrophages), autophagy in neural cells, and bone/cartilage homeostasis. BMAL1 deficiency disrupts circadian oscillations and is associated with diverse disorders, including metabolic syndrome, neurological disease, cancer, immune dysfunction, and altered sleep cycles. Therapeutically, BMAL1 is considered a promising target in chronobiology and metabolic disease, though direct pharmacological targeting remains experimental due to its wide-ranging systemic effects.

Other names
Aryl hydrocarbon receptor nuclear translocator-like protein 1ARNTLbHLHe5MOP3PASD3BMAL1cJAP3TICPAS domain containing 3Brain and muscle ARNT-like 1Class E basic helix-loop-helix protein 5Member of PAS protein 3bHLH-PAS protein JAP3
02

Mechanism of action

Agents modulating clock gene expression may influence BMAL1 by altering its transcriptional activity, post-translational modifications, or dimerization with CLOCK protein. For example: CK1 inhibitors modulate circadian protein stability. REV-ERB agonists/antagonists alter feedback on BMAL1 expression.

03

Biological functions

Regulation of circadian rhythm/cellular clockTranscriptional regulationMetabolic regulationImmune response regulation (e.g., macrophage immunometabolism, inflammatory cytokine control)Regulation of autophagy and lysosomal function (e.g., in astrocytes)Regulation of bone/cartilage metabolism
04

Disease associations

Sleep/wake disorders, circadian rhythm disruptionCancer (metastasis, cell proliferation, links through TGF-β signaling)Metabolic diseases (e.g., diabetes, obesity, hypertension)Neurological diseases (e.g., neurodegeneration, effects mediated through astrocyte autophagy)Autoimmune diseases (e.g., multiple sclerosis)Infertility and reproductive disorders
05

Safety considerations

Challenges include widespread systemic roles for BMAL1 (many cell types, many genes regulated), so targeted inhibition can cause arrhythmicity, metabolic dysregulation, immunological effects (e.g., heightened inflammation), and possible tumorigenesis or impaired tissue homeostasis
06

Interacting drugs

Direct pharmacological modulators are rare, but small-molecule modulators of circadian genes, such as REV-ERB agonists or casein kinase inhibitors, may indirectly affect BMAL1 pathways. No approved drugs directly target BMAL1 in clinical use as of now; research chemicals and experimental ligands have been used in studies.
07

Biomarkers

Disrupted BMAL1 expression/rhythms can indicate circadian misalignment in disorders such as sleep disruption, metabolic syndrome, or certain cancers.BMAL1 and target gene expression (e.g., PER, CRY family) are used in chronobiology research as biomarkers of circadian phase

Beyond the preview

Go deeper on Basic helix-loop-helix ARNT-like protein 1 (BMAL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Basic helix-loop-helix ARNT-like protein 1 (BMAL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call